Anupam Dalal - 14 May 2026 Form 4 Insider Report for Whitehawk Therapeutics, Inc. (WHWK)

Reporting relationship: Director
Issuer ticker: WHWK
Reported as of: 14 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Jul 2026, 16:04:33 UTC
Prior SEC filing: 16 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Stephen Rodin, as Attorney-in-Fact

Key filing fact

Anupam Dalal filed Form 4 for Whitehawk Therapeutics, Inc. (WHWK) on 30 Jul 2026.

Key facts

This page summarizes Anupam Dalal's Form 4 filing for Whitehawk Therapeutics, Inc. (WHWK).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 30 Jul 2026, 16:04.

Change

Previous filing in this sequence was filed on 16 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001602474 Primary reporting owner

Dalal Anupam

Relationship: Director
Address: C/O WHITEHAWK THERAPEUTICS, INC., 2 HEADQUARTERS PLAZA, EAST BUILDING, 11T, MORRISTOWN
Signature: /s/ Stephen Rodin, as Attorney-in-Fact
Signature date: 30 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WHWK transaction

Common Stock

Award

Transaction value
Shares: +1,275,510
Change %: +37%
Price: $3.92^*
Shares after: 4,685,912
Date: 14 May 2026
Ownership: See footnote
Footnotes: F1

WHWK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 1,130
Date: 14 May 2026
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WHWK transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +38,040
Change %
Price: $0.000000^*
Shares after: 38,040
Date: 12 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 38,040
Exercise price: $4.16
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Consists of (i) 3,538,288 shares held by Acuta Capital Fund, LP ("Acuta Capital") and (ii) 1,147,624 shares held by Acuta Opportunity Fund, LP. ("Acuta Opportunity Fund"). Acuta Capital Partners, LLC ("Acuta Partners") is the general partner of each of Acuta Capital and Acuta Opportunity Fund. The Reporting Person is the Chief Investment Officer and Managing Member of Acuta Partners. The Reporting Person has voting and investment authority over all of the shares held by each of Acuta Capital and Acuta Opportunity Fund. Each of Acuta Partners and the Reporting Person disclaim beneficial ownership of the shares of common stock held by each of Acuta Capital and Acuta Opportunity Fund except to the extent of their pecuniary interest therein.

Footnote F2

Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.